<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01865240</url>
  </required_header>
  <id_info>
    <org_study_id>008/12</org_study_id>
    <secondary_id>NHMRC</secondary_id>
    <nct_id>NCT01865240</nct_id>
  </id_info>
  <brief_title>Renal Denervation for Resistant Hypertension</brief_title>
  <acronym>RDNP-2012-01</acronym>
  <official_title>Renal Denervation for Resistant Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baker IDI Heart and Diabetes Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baker IDI Heart and Diabetes Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study investigating the effectiveness of renal denervation in lowering blood
      pressure in people whose blood pressure is not adequately controlled despite treatment with 3
      or more blood pressure lowering drugs. The study is designed to compare the effects of renal
      denervation to a usual care group receiving additional blood pressure lowering drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous studies have shown that the renal denervation procedure is safe and effective in
      reducing blood pressure in patients with resistant hypertension. A total of 100 participants
      with uncontrolled blood pressure, treated with three or more blood pressure lowering
      medications will be recruited into the study. Patients will be assigned to one (1) of two (2)
      groups with the aim of attaining blood pressure control. Participants in group 1 will be
      assigned to renal denervation, participants in group 2 will receive additional
      antihypertensive medication according to current guidelines and best practice in an attempt
      to reach blood pressure targets.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No new participants enrolled. Protocol has been superseded
  </why_stopped>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood pressure control</measure>
    <time_frame>6 months post procedure</time_frame>
    <description>percentage of patients to achieve Blood Pressure (BP) target (BP &lt;140/90mmHg, or &lt;130/80mmHg in diabetic patients) at 6 months post procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of drugs required to reach blood pressure target</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>number of drugs required to reach blood pressure target</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to achieve blood pressure target</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>time to achieve blood pressure target</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in markers of sympathetic nerve activity</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Changes in Muscle Sympathetic Nerve Activity (MSNA), renal and whole body Norepinephrine (NE) spillover</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular Structure and Function</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Change in Left Ventricular mass index, ejection fraction, diastolic filling as assessed by echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Change in Quality of Life as assessed by relevant questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum and Urine Biochemistry</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Plasma renin activity, aldosterone, estimated Glomerular Filtration Rate (eGFR), urine albumin-to-creatinine ratio (UACR), inflammatory markers, 24hour urinary creatinine clearance, sodium, fasting glucose, fasting insulin, c-peptide, Homeostasis Model Assessment (HOMA) index, lipid profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in markers of arterial stiffness</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Change in markers of arterial stiffness including Augmentation Index (AI) and Pulse Wave Velocity (PWV)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Renal Denervation Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants randomised to undergo the renal denervation procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renal Denervation</intervention_name>
    <description>Renal Denervation Catheter</description>
    <arm_group_label>Renal Denervation Group</arm_group_label>
    <other_name>Symplicity Renal Denervation Catheter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  systolic BP ≥140mmHg or ≥130mmHg for patients with diabetes

          -  concurrent treatment with ≥3 anti-hypertensive drugs

        Exclusion Criteria:

          -  renal artery anatomy ineligible for treatment

          -  eGFR &lt;15mL/min/1.73m2 (using Modification of Diet in Renal Disease (MDRD) calculation)

          -  female participants of childbearing potential must have negative pregnancy test prior
             to treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Schlaich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baker IDI Heart &amp; Diabetes Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baker IDI Heart &amp; Diabetes Inst</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2013</study_first_submitted>
  <study_first_submitted_qc>May 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2013</study_first_posted>
  <last_update_submitted>July 20, 2016</last_update_submitted>
  <last_update_submitted_qc>July 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal denervation</keyword>
  <keyword>blood pressure</keyword>
  <keyword>cardiovascular risk</keyword>
  <keyword>target organ damage</keyword>
  <keyword>sympathetic activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

